The outcomes of chronic myeloid leukemia patients with molecular warning responses under imatinib according to the European LeukemiaNet (ELN) 2013 recommendations

Publication date: Available online 4 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Teoman Soysal, Ahmet Emre Eskazan, Istemi Serin, Sevil Sadri, Dilek Keskin, Nurgul Ozgur Yurttas, Selin Berk, Isil Erdogan Ozunal, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren, Zafer Baslar, Ugur Ozbek, Yildiz AydinAbstractIn the European LeukemiaNet (ELN) 2013 recommendations, chronic myeloid leukemia (CML) patients with warning response (WR) were suggested to be monitored closely continuing with the same tyrosine kinase inhibitor (TKI). Differently, the guidelines of National Comprehensive Cancer Network considers switching to another TKI as an option. We retrospectively evaluated 73 CML patients receiving frontline imatinib, who were followed and managed in accordance to ELN recommendations. We compared patients with molecular WR to cases with optimal response (OR) and failure regarding short- and long-term outcomes. The cumulative major molecular response (MMR) rates in patients with OR were significantly higher for any timepoint than those achieved by WR group. Patients with WR at 3 months had significantly inferior failure-free survival (FFS) than optimal responders, but overall survival (OS) was similar. For 6- and 12-months, WR and OR groups had similar FFS and OS. Twenty out of 23 patients with WR at 12 months, achieved MMR under imatinib. It takes longer to get to ELN timepoints with imatinib than second-generation TKIs (2GTKIs). A minority of the patients with WR...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research